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ABSTRACT

Cisplatin is an anti-cancer drug effective against several cancers which can
produce the serious side-effect of hearing loss. Curcumin, a natural plant compound, can
increase the activity of cisplatin against cancer and counteract cisplatin’s effect against
hearing. Because curcumin exhibits poor bioavailability, there is considerable interest in
developing synthetic curcumin analogs (curcuminoids) that are more soluble and which
retain anti-cancer activity and otoprotective function. This study investigated whether
two curcuminoids, EF-24 and CLEFMA, increase the cytotoxic and ototoxic effects of
cisplatin against the lung cancer cell line, A549, and the colorectal cancer cell line,
Caco2. Cytotoxicity was measured by using the colorimetric 3-(4,5-dimethylthiazol-2yl)-2,5-diphenyltetrazolium bromide (MTT) assay. Ototoxicity was quantified by
measuring hearing thresholds acquired by the auditory evoked potential technique in a
zebrafish (Danio rerio) model. The results of this study indicate that a combination of
cisplatin with either CLEFMA or EF-24, produces a dose-dependent effect against the
cancer cell-lines which is not synergistic or additive. The hearing tests showed that both
curcuminoids could prevent hearing loss caused by cisplatin treatment. However, the
curcuminoid vehicle, DMSO, could also play a role in the effect on hearing. These
results suggest that curcuminoid treatment may increase the effect of cisplatin against
these cancers and might also reduce hearing damage produced by cisplatin treatment.
Future research is needed to investigate the signaling pathways that regulate the function
of cisplatin, CLEFMA, EF-24 and DMSO in cancer and auditory physiology.
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INTRODUCTION

Cancer is the second leading cause of death in the world, making the development
of new chemotherapeutics an urgent priority (Ferlay et al. 2012; Cheung-Ong et al.
2013). One drug design approach, utilized in the platinum-based compound, cisplatin, is
to induce DNA damage, which activates apoptotic pathways and initiates mitochondrialdependent reactive oxygen species (ROS) release (Cepeda et al. 2007; Marullo et al.
2013). Another approach is to target a broad set of pathways, and is exemplified by the
phytochemical, curcumin, which is able to act against various cancers by modulating the
cell cycle, apoptotic mechanisms, microRNAs, the proteasome, Wnt/β-catenin and NFκB signaling, as well as several protein kinases (Tuorkey 2014). The diverse mechanistic
targeting of these two drugs suggests that combining them could produce an additive or
even synergistic response beyond their individual effects. However, there are serious
limitations present in combining cisplatin with curcumin. Cisplatin can cause multiple
side-effects, including permanent hearing-loss by releasing ROS (Sergent et al. 2002;
Cepeda et al. 2007; Benard et al. 2014; Salehi et al. 2014; Chen et al. 2015; Horibe et al.
2015). Elevated hearing threshold have been reported in 75–100% of patients treated
with cisplatin (Mckeage 1995). Although curcumin can act as an otoprotectant and
counteract cisplatin resistance mechanisms (Salehi et al. 2014; Chen et al. 2015;
Shanmugam et al. 2015), curcumin exhibits very poor bioavailability, which restricts its
efficacy (Teiten et al. 2014; Fridlender et al. 2015). To address the deficiencies found
with curcumin solubility, researchers have developed synthetic curcumin alternatives
(curcuminoids) that retain anti-cancer activity, but also possess improved bioavailability.
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However, little is known about whether these curcuminoids enhance anti-cancer effects
when combined with cisplatin or if they can counteract its side-effects.
Two new curcuminoids, (3E,5E)-3,5-bis[(2-fluorophenyl)methylene]-4piperidinone (EF-24) and 4-[3,5-Bis[(2-chlorophenyl)methylene]-4-oxo-1-piperidinyl]-4oxo-2-butenoic acid (CLEFMA), demonstrate significant anti-cancer effects and
improved solubility. EF-24 causes cell cycle arrest followed by alteration of
mitochondrial function leading to apoptosis, increased ROS production and decreased
cell proliferation in cancer cell-lines (Adams et al. 2005). Another study has shown that
EF-24 induces apoptosis and suppresses cancer cell viability more effectively than
curcumin in cisplatin-sensitive and -resistant cell-lines (Tan et al. 2010). Interestingly,
this study also demonstrated that EF-24 acts as an anti-oxidant (Tan et al. 2010), which
suggests that this curcuminoid might be able to counteract cisplatin modulated ROS
release and damage to auditory hair cells. Unlike EF-24, CLEFMA has been shown to
reduce proliferation in a lung cancer cell-line through an autophagic, and not apoptotic,
mechanism (Lagisetty et al. 2011). CLEFMA has also been shown to upregulate ROS
release from the mitochondria in lung cancer cells by deregulating redox pathways
(Sahoo et al. 2012). Surprisingly, this study also found that ROS release was not
increased, nor was cellular viability decreased in a normal lung fibroblast cell-line,
suggesting that CLEFMA may not target non-cancerous cells (Sahoo et al. 2012).
Therefore, these studies indicate that EF-24 and CLEFMA may function through distinct
pathways and could potentially act against cancer without producing ROS that cause
auditory side-effects.
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My project examined if EF-24 and CLEFMA could enhance cisplatin’s activity
against cancer cell viability and reduce hearing damage caused by cisplatin treatment.
The first phase utilized the colorimetric 3-(4,5-dimethylthiazol-2-yl)-2,5diphenyltetrazolium bromide (MTT) assay to determine if these curcuminoids altered
cisplatin’s effect on cellular viability in the small-cell lung cancer line, A549, and the
colorectal cancer line, Caco2. Then, the second phase applied the auditory evoked
potential (AEP) technique in a zebrafish (Danio rerio) inner ear model to determine if the
curcuminoids reduced auditory side-effects produced by cisplatin treatment. Thus, this
project investigated if these two new curcuminoid compounds act synergistically with
cisplatin against cancer and also counteract cisplatin-mediated hearing loss.
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METHODOLOGY

Cell viability assay
The colorimetric MTT assay was used to determine if the two curcuminoids,
EF-24 and CLEFMA, enhanced the effect of cisplatin against cancer cell viability.
The small-cell lung cancer cell line, A549 (ATCC), was seeded in 96-well plates in
F12K media (with 10% fetal bovine serum and 1% penicillin/streptomycin
supplementation) at a density of 5,000 cells per well and incubated for 24 hours at
37°C in 5% CO2. Then, the 96-well plates were treated with a dilution series (500,
50, 5, 0.5, 0.05 or 0.005 µM) of either EF-24 or CLEFMA (solubilized in dimethyl
sulfoxide, DMSO) for 72 hours at 37°C in 5% CO2 in replicates of six. In addition, a
negative control (cells with media only), positive control (Triton X-100) and media
only blanks were run in replicates of six. After 72 hours elapsed, the MTT assay was
run for 2 hours. The media was then ejected from all the wells, and solubilization
solution was added. The plates were vortexed for 15 minutes, and then their
absorbance was determined using a spectrophotometer at 570 and 690 nm.
IC50 values of cisplatin and both curcuminoids were calculated in GraphPad Prism
(version 6) using a sigmoidal, four parameter logistic equation. Then, another set of
plates were prepared using the same procedure as above except that after 24 hours,
the experimental wells were treated with the IC50 value of cisplatin (10 µM of
cisplatin in A549 and 12 µM of cisplatin in Caco2 solubilized in media) for 24 hours
followed by treatment with a curcuminoid for 48 hours using the same dilution series
and then the MTT assay as before. A separate plate with a DMSO only treatment was
4

prepared using the same dilution series and protocol above to determine whether it
affected cellular viability.

Auditory evoked potentials
The auditory evoked potential (AEP) technique was used in a zebrafish model to
assess whether the curcuminoids counteract cisplatin-induced hearing side-effects. AEP
recording is a commonly employed electrophysiology technique used to assess hearing in
fishes (Smith et al. 2006; Smith et al. 2011; Uribe et al. 2013). Zebrafish were obtained
from commercial suppliers and maintained individually in 170 liter tanks. Mean (± S.E.)
standard length and mass of the zebrafish (N=45) was 31.0 (± 0.66) millimeters and 0.47
(± 0.03) grams, respectively. Zebrafish were microinjected with cisplatin, a curcuminoid,
or cisplatin with a curcuminoid. The cisplatin vehicle was 0.9% sodium chloride, while
the curcuminoid vehicle was DMSO. Separate sodium chloride and DMSO vehicle
controls were also performed. For cisplatin, the injection was based on the ratio of 25
mg/kg (cisplatin mg/kg body weight). For both curcuminoids, we injected 5 mg/kg.
Hearing tests were performed on cisplatin, EF-24, CLEFMA and the two vehicle group
treatment fish 48 hours after injection. However, for treatments using a combination of
cisplatin and either EF-24 or CLEFMA, the cisplatin was injected first and then after 24
hours, a curcuminoid was injected, and the fish were placed back into an aquarium for an
additional 24 hours before AEP testing.
For each treatment category, a minimum of six zebrafish (range: 6-8) were
injected. After the treatment interval, the fish were subjected to the auditory evoked
potential technique. Briefly, the fish were lightly anaesthetized with tricaine
5

methanesulfonate (MS-222) and then placed into a mesh harness suspended 6 cm from
the water surface and 22 cm above a University Sound UW-30 underwater speaker
(Electro-Voice, Burnsville, MN) in a 19-L tank containing 27-28C water. Electrical
interference was minimized by keeping the tank within a Faraday cage. This cage was
located within a sound-attenuation room to reduce background noise (Whisper Room,
Inc., Knoxville, TN). Three stainless steel subdermal electrodes (27 gauge; Rochester
Electro-Medical, Inc., Tampa, FL) were attached 1-2 mm sub dermally to the fish- a
recording electrode over the brainstem, a reference electrode between the nares, and a
ground electrode in the tail musculature. Sound stimuli were presented and AEP
waveforms collected using BioSig software running on a TDT physiology system
(Tucker Davis Technologies, Inc., Alachua, FL). Pure tone pip stimuli at eight different
frequencies (100, 250, 400, 600, 800, 1000, 1500 and 3000 Hz) were presented to the
fish. Each frequency was tested by decreasing decibel levels in 5 dB steps until an AEP
trace was no longer visible.
The sound pressure levels of each frequency were confirmed using a calibrated
hydrophone (calibration sensitivity of -195 dB re 1 V/µPa: ± 3 dB, 0.02-10 kHz
omnidirectional, GRAS Type 10CT, Denmark), placed in the same location where fish
were held during AEP recording. The last sound pressure level at which an AEP trace
was visible was noted as the threshold for each frequency. The collective thresholds for
these eight frequencies were used to produce audiograms. All procedures were
conducted under the approval of the Western Kentucky University Institutional Animal
Care and Use Committee (Animal Welfare Assurance # A3558-01).
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Statistical analysis
For the MTT assays, a two-way ANOVA using a Sidak’s multiple comparisons
test, with curcuminoid concentration and cisplatin treatment as factors, was performed.
For the AEPs, a two-way ANOVA, with frequency and injection treatment as factors,
was used. When the overall ANOVA exhibited significant treatment effects, a Tukey’s
multiple comparisons post hoc test was performed. A p-value of <0.05 was considered to
be significant. Mean and standard error of the mean (SEM) was calculated for each
treatment group and used to plot the data. All statistical analysis was processed in the
statistical modeling program Prism (GraphPad Prism version 6, La Jolla, California,
USA).
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RESULTS

Cellular Viability Assay
We determined the cellular viability of the selected cancer lines using the MTT
assay for each treatment condition. The IC50 value for cisplatin was determined to be 10
µM in the A549 cancer cell line; in the Caco2 cancer cell line, the IC50 value for cisplatin
was determined to be 12 µM. Furthermore, the IC50 values for EF-24 and CLEFMA in
both cell lines were determined to be 2 µM and 15 µM respectively.
In the A549 cell line, we found a dose-dependent decrease in the absorbance
values, indicating a decrease of cellular viability when cells were treated with either
CLEFMA or cisplatin and CLEFMA. CLEFMA-treated cells had higher cell viability
than CLEFMA and cisplatin-treated cells, although this effect was only significant at 0.5
µM CLEFMA (Figure 1). There was no significant difference in cell viability between
EF-24 and EF-24 plus cisplatin-treated cells, although a concentration-dependent effect
was present (Figure 1).
For the Caco2 cell line, there was also a dose-dependent decrease in cellular
viability with increased concentration of either the curcuminoid, or either curcuminoid
plus cisplatin. The MTT assay showed lower absorbance values (i.e., lower cell viability)
for the CLEFMA and cisplatin treatment when compared to CLEFMA alone, although
they were significantly different only at 500 µM CLEFMA (Figure 2). For EF-24 and
cisplatin, lower absorbance values were shown compared to EF-24 controls, although
they were significantly different only at 0.5 µM EF-24 (Figure 2). In both A549 and
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Caco2 cell lines, the DMSO control showed no effect on the viability of the cancer cells,
as cell viability was similar across all DMSO concentrations (Figure 3).

Auditory Evoked Potentials
Treatment with 0.9% sodium chloride (NaCl) and DMSO resulted in a typical
zebrafish audiogram (Uribe et al. 2013). Cisplatin treatment caused an approximately 10
dB upward threshold shift in the audiograms at 800, 1000, and 1500 Hz relative to NaCl
controls (Fig. 4A). Treatment with the curcuminoids showed a slight increase of
approximately 5 dB in hearing thresholds at three frequencies (800, 1000, and 3000Hz)
when compared to the vehicle for the curcuminoids, DMSO (Figure 4B). Across most
frequencies in the audiogram, cisplatin-injected zebrafish exhibited significantly higher
hearing thresholds than those of zebrafish injected with cisplatin plus either EF-24,
CLEFMA, or DMSO, showing that these compounds can mitigate cisplatin-induced
hearing loss in zebrafish (Figure 5). This protective effect was more prominent at
intermediate frequencies at which cisplatin-induced threshold shifts were the greatest.
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Figure 1. Absorbance at 570 nm of formazan dye in the A549 cancer cell line as a
function of concentration of (A) CLEFMA with and without cisplatin and (B) EF-24 with
and without cisplatin. *P  0.05.
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Figure 2. Absorbance at 570 nm of formazan dye in the Caco2 cancer cell line as a
function of concentration of (A) CLEFMA with and without cisplatin and (B) EF-24 with
and without cisplatin. *P  0.05.
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Figure 3. Absorbance at 570 nm of formazan dye in the (A) A549 and (B) Caco2 cancer
cell lines as a function of concentration of DMSO.
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Figure 4. Hearing thresholds as a function of frequency of tone pip stimuli in (A)
cisplatin, sodium chloride, and DMSO-microinjected zebrafish and (B) CLEFMA, EF24, and DMSO-injected zebrafish. *P  0.05, compared with cisplatin (A) or vehicle (B).
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Figure 5. Hearing thresholds as a function of frequency of tone pip stimuli in cisplatin,
cisplatin and EF-24, cisplatin and CLEFMA, and cisplatin and DMSO-microinjected
zebrafish. At 100, 250, and 600 Hz, cisplatin is significantly different from the cisplatin
+ CLEFMA, cisplatin + DMSO; cisplatin + EF-24 is statistically different from cisplatin
+ CLEFMA and cisplatin + DMSO. At 800 Hz, cisplatin is statistically different from
cisplatin + EF-24, cisplatin + DMSO, and cisplatin + CLEFMA; cisplatin + EF-24 is
statistically different from cisplatin + DMSO and cisplatin + CLEFMA. At 1000, 1500,
and 3000 Hz, cisplatin is significantly different from cisplatin + EF-24, cisplatin +
DMSO, and cisplatin + CLEFMA. *P  0.05 for all treatment conditions.
14

DISCUSSION

Chemotherapy often combines therapeutic agents to enhance the effect of
individual drugs while simultaneously reducing the side-effects produced by one of these
components alone. This study indicates that a combination of cisplatin with either
CLEFMA or EF-24 produces a dose-dependent effect against two cancer cell-lines and
may also prevent hearing loss from cisplatin treatment in a zebrafish auditory model.
Increasing CLEFMA or EF-24 concentration decreased cancer cell viability and the
cisplatin co-treatment produced an equivalent effect or further reduced viability.
Treatment with either CLEFMA or EF-24 can counteract hearing loss caused by
cisplatin, but there could be an effect from the DMSO vehicle. These results suggest that
cisplatin and both curcuminoids have a compatible but not synergistic or additive effect
against these two cancer cell-lines. Further, these curcuminoids may prevent cisplatinmodulated hearing loss but the timing of curcuminoid treatment either before or after
cisplatin exposure and the curcuminoid vehicle used may be important factors to
consider.
This study attempted to identify synergisms between cisplatin and the two
curcuminoids, CLEFMA and EF-24, by measuring their effects on cancer cell viability.
Co-administration of curcumin with cisplatin can sensitize cancer cells that normally are
not responsive to cisplatin treatment (Mimeault and Batra, 2011; Huq et al. 2014).
Curcumin can inhibit the FA/BRCA pathway in cisplatin resistant A549 cells leading to
enhanced apoptosis and cell death (Chen et al. 2015). Similarly, curcumin can improve
the efficacy of cisplatin in the A549 cell line by targeting p21 and cyclin D1 leading to
15

increased apoptosis (Baharuddin et al. 2016). Cisplatin induces mechanisms associated
with apoptosis and mitochondrial-mediated ROS release that cause cancer cell death
(Knox et al. 1986; Jamieson et al. 1999; Cepeda et al. 2007; Wang et al. 2010; Marullo et
al. 2013; Choi et al. 2015; Zou et al. 2015). Curcumin has been shown to reduce ROS
release in cancer cells via a mitochondrial dependent pathway (Jung et al. 2016) and
could potentially negate cisplatin’s effect to promote mitochondrial ROS release and kill
cancer cells. However, studies of CLEFMA and EF-24 suggest that these two
curcuminoids suppress cancer by acting through distinct pathways. CLEFMA prevents
cancer proliferation by activating a non-apoptotic autophagic pathway and promotes
increased ROS production from the mitochondria (Lagisetty et al. 2011; Sahoo et al.
2012). EF-24 reduces cancer proliferation by signaling through an apoptotic pathway
and, like CLEFMA, increases mitochondrial ROS release (Adams et al. 2005;
Selvendiran et al. 2007; Subramaniam et al. 2008; Tan et al. 2010; Yadav et al. 2013).
These results suggest that either curcuminoid could act to enhance cisplatin’s effect by
amplifying the same pathway, e.g., mitochondrial ROS release and apoptosis, or by
acting alongside cisplatin via a distinct pathway, e.g., CLEFMA’s promotion of
autophagy.
Synergistic anti-cancer activity between cisplatin and other drugs can be
identified using the MTT cellular viability assay (Onen et al. 2015; Tian et al. 2017). My
MTT results in the A549 cell line (Figure 1) show that treating cells with 10 µM cisplatin
in a concentration series (500 µM to .05 µM) of either CLEFMA or EF-24 does not
produce a significant difference in cellular viability from either curcuminoid alone in the
same concentration series in all but one concentration (0.5 µM CLEFMA). The MTT
16

assay results for the Caco2 cell line using the same concentration series for either
curcuminoid with or without treatment with 12 µM cisplatin also produced only two data
points that were significantly different (500 µM CLEFMA and 0.5 µM EF-24: Figure 2).
Results for both the A549 or Caco2 do not suggest either an additive or synergistic effect
is produced by combining either curcuminoid with cisplatin. This result implies a lack of
targeting, by either CLEFMA or EF-24, of a pathway that enhances cisplatin activity.
However, an alternative interpretation is that either curcuminoid might modulate a
pathway that nullifies cisplatin’s effect but that the curcuminoid can still signal through
other cancer targeting pathways causing a decrease in cancer cell viability. This
interpretation is supported by the data which shows that there is a general decline in
cellular viability as the concentration of the curcuminoid is increased (Figure 1 and 2).
The curcuminoid treatments used the solvent, DMSO, which can neutralize
cisplatin (Fischer et al. 2008; Hall et al. 2014). Although this could explain the absence
of an enhanced effect on viability from combining cisplatin with a curcuminoid, cisplatin
treatment occurred 24 hours prior to curcuminoid/DMSO treatment. It has been shown
that significant cisplatin uptake to the nucleus occurs within 3 hours (Park et al. 2012), so
it is unlikely that introducing DMSO 24 hours after cisplatin treatment would cause
DMSO to directly neutralize cisplatin. My MTT results testing the effect of DMSO
treatment in both the A549 and Caco2 cell lines indicates that this solvent itself does not
influence cellular viability (Figure 3). However, DMSO might function as an antioxidant
to neutralize ROS produced during a later stage of the cisplatin-induced cell death
pathway. Although DMSO has been shown to act as an antioxidant that counteracts the
effect of pro-oxidant compounds in brain tissue homogenates (Sanmartin-Suarez et al.,
17

2011), no study has examined the effect of this solvent on cisplatin-modulated ROS
production. Thus, the cellular viability assay does not identify a synergistic or additive
effect from combining either CLEFMA or EF-24 with cisplatin but does support a
concentration dependent effect against both cancer cell-lines from these curcuminoids.
Examination of whether CLEFMA and EF-24 compounds could counteract
hearing side-effects produced by cisplatin treatment was also conducted. Cisplatin is an
ototoxin which damages auditory hair cells resulting in reduced hearing thresholds
(Karasawa et al. 2015; Waissbluth et al. 2015). In the cochlea, cisplatin initially damages
DNA leading to an increase in ROS generation that alters the activity of many enzymes
leading ultimately to apoptotic hair cell damage and death (Deavall et al. 2012; Schacht
et al. 2012; Paken et al. 2016). Curcumin treatment can induce hemeoxygenase, an
antioxidant enzyme, and counteract auditory threshold shifts caused by cisplatin (Fetoni
et al. 2014). A subsequent study in the same laboratory implicated STAT3 and Nrf2
signaling in curcumin’s otoprotective effect against cisplatin (Fetoni et al. 2015). No
studies have yet characterized the effect of either CLEFMA or EF-24 on hearing. It is
known that EF-24 can increase ROS release in cancer cells, but can also act as an antioxidant (Adams et al. 2005; Tan et al. 2010). This suggests that if EF-24 acted as an antioxidant in auditory hair cells, then it could counteract ROS release caused by cisplatin
treatment and possibly prevent auditory hair cell apoptosis. CLEFMA has been shown to
increase ROS release in cancer cells, but studies show that it does not increase ROS
levels in normal cells (Lagisetty et al. 2011; Sahoo et al. 2012). This could mean that
CLEFMA may not act as an ROS scavenger in auditory hair cells, but it is not known
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whether this curcuminoid’s activity against ROS or associated mechanisms would be
altered in hair cells that have become physiologically aberrant due to cisplatin exposure.
The zebrafish auditory electrophysiology model can detect threshold shifts caused
by ototoxins (Uribe et al. 2013). As cisplatin causes damage to the hair cells of the
zebrafish inner ear (Giari et al. 2012), the AEP technique should detect auditory threshold
shifts produced from cisplatin treatment and identify otoprotective effects from
curcuminoids. My AEP results showed that cisplatin caused significant hearing threshold
shifts of 10 dB or more above its NaCl vehicle and the curcuminoid vehicle, DMSO at
three frequencies (Figure 4A). This suggests that cisplatin creates an ototoxic effect
relative to both vehicle treatments. A similar experiment compared the two curcuminoids
with their DMSO vehicle and found that a significant threshold shift occurred for
CLEFMA at only one frequency, and at two frequencies for EF-24 with less than a 5 dB
effect at these three endpoints (Figure 4B). These results suggest that both curcuminoids
generally do not induce an ototoxic effect.
The AEP experiments performed on zebrafish treated initially with cisplatin and
either a curcuminoid or DMSO suggest that DMSO could act as an otoprotectant. Both
curcuminoids significantly reduced threshold shifts at multiple frequencies (Figure 5).
However, the CLEFMA data suggests that this curcuminoid might be a better
otoprotectant than EF-24, as the hearing thresholds in zebrafish treated with CLEFMA +
cisplatin were significantly lower than EF-24 + cisplatin. Furthermore, treating cisplatininjected fish subsequently with just DMSO, caused a reduction in threshold shifts at the
same frequencies that CLEFMA did and produced an almost identical audiogram. These
results suggest that DMSO, and not the curcuminoid, could be responsible for the
19

otoprotective effect. As DMSO can neutralize cisplatin (Fischer et al. 2008; Hall et al.
2014), DMSO was injected with or without a curcuminoid 24 hours after the initial
cisplatin injection. This protocol was premised on results from biochemical assays where
significant platinum uptake into the nucleus occurred within 3 hours of cisplatin
treatment (Park et al. 2012). Although, this study was performed in dissociated cancer
cells and intact auditory tissue may exhibit different and slower platinum uptake
physiology.
DMSO can, depending on the molecular target, act as both an antioxidant and
pro-oxidant (Sanmartin-Suarez et al., 2011) and in the former capacity it could target and
neutralize ROS generated downstream from cisplatin treatment. This could mean that the
temporal separation in these experiments between cisplatin and DMSO injection may be
insufficient to prevent DMSO from counteracting the downstream effects from cisplatin
and was responsible for the reduced threshold shifts. However, one study of DMSO and
cisplatin in rats showed that intraperitoneally injecting cisplatin immediately after an
intratympanic injection of DMSO caused significant hearing threshold shifts (RoldanFidalgo et al. 2014). Thus, temporally proximate treatments of cisplatin and DMSO do
not necessarily negate the ototoxic effect of this platinum-based drug. Evidently,
additional research is needed to more precisely determine the mechanistic interplay
between cisplatin, CLEFMA, EF-24 and DMSO in cancer cell and auditory physiology.
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